PROCEPT BioRobotics (US:PRCT) Globenewswire·2025-07-23 12:00Core Viewpoint - PROCEPT BioRobotics Corporation has successfully completed three prostate cancer procedures using Aquablation therapy in an Ambulatory Surgery Center, marking a significant milestone in the treatment of localized prostate cancer [1][3]. Group 1: Aquablation Therapy and Clinical Trial - Aquablation therapy is an image-guided, minimally invasive surgical procedure that utilizes a robotically-controlled waterjet to remove diagnosed cancer and most of the prostate [2]. - The WATER IV PCa Trial is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation therapy with radical prostatectomy for men with localized prostate cancer [2]. - The trial aims to evaluate the safety and efficacy of Aquablation therapy for men with Grade Group 1 to 3 localized prostate cancer [2]. Group 2: Treatment Setting and Outcomes - Dr. Rahul Mehan has chosen to conduct the randomized Aquablation therapy trial at an Ambulatory Surgery Center, demonstrating that early-stage prostate cancer can be safely treated in this setting [3]. - All procedures were completed successfully, with patients discharged the same day without complications, indicating a safe prostate resection [3]. - The approach of using Aquablation therapy could lead to a more scalable and cost-effective care model in the evolving healthcare market [3]. Group 3: Industry Impact and Future Prospects - The unique design of the WATER IV PCa trial focuses on harm reduction and could potentially change the treatment paradigm for localized prostate cancer among millions of men [3]. - The FDA's approval of the IDE for this trial reflects a thorough review process and opens up possibilities for this novel treatment approach [3]. - PROCEPT BioRobotics is committed to advancing patient care through transformative urology solutions, with a significant body of clinical evidence supporting the benefits of Aquablation therapy [5].